미국의 에피제네틱스 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 기술별, 용도별, 최종 용도별, 부문별 예측(2024-2030년)

U.S. Epigenetics Market Growth & Trends:

The U.S. epigenetics market size is anticipated to reach USD 13.10 billion by 2030, growing at a CAGR of 14.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of cancer and chronic diseases, advancements in epigenetic research and technologies, rising investment in biomedical research, and increasing adoption of personalized medicine are anticipated to increase the demand for epigenetics over the forecast period.

The COVID-19 pandemic has had a positive impact on the market. The pandemic spurred a significant increase in research activities related to understanding the virus and its effects on human health. This included epigenetic research to study how COVID-19 affects gene expression and immune responses. Consequently, there was increased funding from both government and private sectors for epigenetic studies related to COVID-19.

Moreover, companies have increased investments in the development of epigenetics products. Many biotechnology and pharmaceutical companies have increased their research and development budgets to explore the role of epigenetics in disease mechanisms and treatment responses. This influx of funding has accelerated the pace of discoveries and innovations in the field. The transition from external funding to domestic investment in health systems underscores the need for innovative solutions. Epigenetics, embedded in advancing healthcare, is projected to transform the phase by offering solutions for improving health outcomes.

However, the growth of the market is constrained by a scarcity of skilled professionals. The complex nature of epigenetics demands a deep understanding of genetics, molecular biology, and data analysis. This shortage can decelerate research & technological progress, hinder complex data analysis crucial for insights, slow clinical translation, and hamper educational initiatives. This is anticipated to hamper the growth of the market to a certain extent.

U.S. Epigenetics Market Report Highlights:

• Reagents dominated the product segment with the largest revenue share of 32.5% in 2023. Reagents are versatile and used in a wide range of applications, including basic research, clinical diagnostics, and drug development. On the other hand, services are expected to grow at the fastest CAGR over the forecast period.
• The DNA methylation held the largest market share in 2023 for the technology segment. DNA methylation is one of the key epigenetic modifications that plays a vital role in regulating gene expression. However, on the other hand, histone acetylation is expected to grow at the fastest CAGR over the forecast period.
• The oncology held the largest market share in 2023 for the application segment. This is attributed to the growing prevalence of cancer. However, on the other hand, non-oncology is expected to grow at the fastest CAGR over the forecast period.
• Based on end-use, academic research dominated the segment with the largest revenue share in 2023. This is attributed to the increasing number of clinical studies which are being conducted in academic institutes and the growing funding for research activities. On the other hand, clinical research is anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. End-use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Rising geriatric patient population
    • 3.2.1.3. Increasing government initiatives
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of standardization in epigenetics-based diagnostics
    • 3.2.2.2. Lack of skilled professionals
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Epigenetics Market: Product Business Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Epigenetics Market Product Movement Analysis
• 4.3. U.S. Epigenetics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Reagents
  • 4.4.1. Reagents market estimates and forecast, 2018 - 2030 (USD Million)
• 4.5. Kits
  • 4.5.1. Kits market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5.2. ChIP Sequencing Kit
    • 4.5.2.1. ChIP sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5.3. Whole Genomic Amplification Kit
    • 4.5.3.1. Whole genomic amplification kit market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5.4. Bisulfite Conversion Kit
    • 4.5.4.1. Bisulfite conversion kit market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5.5. RNA Sequencing Kit
    • 4.5.5.1. RNA sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5.6. Others
    • 4.5.6.1. Others market estimates and forecast, 2018 - 2030 (USD Million)
• 4.6. Instruments
  • 4.6.1. Instruments market estimates and forecast, 2018 - 2030 (USD Million)
• 4.7. Enzymes
  • 4.7.1. Enzymes market estimates and forecast, 2018 - 2030 (USD Million)
• 4.8. Services
  • 4.8.1. Services market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Epigenetics Market: Technology Business Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Epigenetics Market Technology Movement Analysis
• 5.3. U.S. Epigenetics Synthesis Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 5.4. DNA Methylation
  • 5.4.1. DNA methylation market estimates and forecast, 2018 - 2030 (USD Million)
• 5.5. Histone Methylation
  • 5.5.1. Histone methylation market estimates and forecast, 2018 - 2030 (USD Million)
• 5.6. Histone Acetylation
  • 5.6.1. Histone acetylation market estimates and forecast, 2018 - 2030 (USD Million)
• 5.7. Large Non - coding RNA
  • 5.7.1. Large non - coding RNA market estimates and forecast, 2018 - 2030 (USD Million)
• 5.8. MicroRNA Modification
  • 5.8.1. MicroRNA modification market estimates and forecast, 2018 - 2030 (USD Million)
• 5.9. Chromatin Structures
  • 5.9.1. Chromatin structures market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Epigenetics Market: Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Epigenetics Market Application Movement Analysis
• 6.3. U.S. Epigenetics Synthesis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.2. Solid Tumors
    • 6.4.2.1. Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.3. Liquid Tumors
    • 6.4.3.1. Liquid tumors market estimates and forecast, 2018 - 2030 (USD Million)
• 6.5. Non-oncology
  • 6.5.1. Non-oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.2. Inflammatory Diseases
    • 6.5.2.1. Inflammatory diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.3. Metabolic Diseases
    • 6.5.3.1. Metabolic diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.4. Infectious Diseases
    • 6.5.4.1. Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.5. Cardiovascular Diseases
    • 6.5.5.1. Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.6. Others
    • 6.5.6.1. Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. U.S. Epigenetics Market: End-use Business Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Epigenetics Market End-use Movement Analysis
• 7.3. U.S. Epigenetics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 7.4. Academic Research
  • 7.4.1. Academic research market estimates and forecast, 2018 - 2030 (USD Million)
• 7.5. Clinical Research
  • 7.5.1. Clinical research market estimates and forecast, 2018 - 2030 (USD Million)
• 7.6. Hospitals & Clinics
  • 7.6.1. Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
• 7.7. Pharmaceutical & Biotechnology Companies
  • 7.7.1. Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)
• 7.8. Others
  • 7.8.1. Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2023
• 8.4. Participant's Overview
  • 8.4.1. Roche Diagnostics
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product & service benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Thermo Fisher Scientific, Inc.
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product & service benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Danaher
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product & service benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Eisai Co. Ltd.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product & service benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Novartis AG
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product & service benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Element Biosciences, Inc.
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product & service benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Dovetail Genomics LLC.
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product & service benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Illumina, Inc.
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product & service benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Promega Corporation.
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product & service benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Abcam plc.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product & service benchmarking
    • 8.4.10.4. Strategic initiatives